Literature DB >> 8500220

Antitumor activity and cytotoxicity of a new ankinomycin derivative, 3'-,11-dibutyryl ankinomycin.

S Ishii1, Y Satoh, T Tsuruo.   

Abstract

Ankinomycin is a new antitumor antibiotic found in the culture broth of Streptomyces sp. SF2587. Ankinomycin showed marked cytotoxicity and antitumor activity against some murine leukemias, but the activity against murine solid tumors was rather weak because of its strong acute toxicity. We synthesized ankinomycin acyl derivatives and examined their antitumor activity. Among the derivatives, 3',11-dibutyryl ankinomycin (AN1006) exhibited the highest antitumor activity. The antitumor activity of AN1006 was dependent on the administration schedule, and on the most effective schedule, AN1006 showed activity comparable with that of Adriamycin (ADM) against murine solid tumors and leukemias. AN1006 showed a cytotoxic spectrum different from that of ADM, exhibiting cytotoxicity stronger than that of ADM against colon carcinoma, stomach carcinoma, and some leukemia cell lines. According to these in vitro effects, AN1006 showed antitumor activity superior to and equal to that of ADM against human colon xenografts and stomach carcinoma xenografts in athymic nude mice, respectively. AN1006 was effective against multidrug-resistant tumors in vitro and in vivo. AN1006 is an interesting candidate for further evaluation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8500220     DOI: 10.1007/BF00685831

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  18 in total

1.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.

Authors:  C B Lozzio; B B Lozzio
Journal:  Blood       Date:  1975-03       Impact factor: 22.113

2.  Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones.

Authors:  T Tsuruo; H Iida-Saito; H Kawabata; T Oh-hara; H Hamada; T Utakoji
Journal:  Jpn J Cancer Res       Date:  1986-07

3.  Antitumor activity of ankinomycin.

Authors:  S Ishii; M Nagasawa; Y Kariya; O Itoh; H Yamamoto; S Inouye; S Kondo
Journal:  J Antibiot (Tokyo)       Date:  1989-10       Impact factor: 2.649

4.  ATP/Mg2+-dependent binding of vincristine to the plasma membrane of multidrug-resistant K562 cells.

Authors:  M Naito; H Hamada; T Tsuruo
Journal:  J Biol Chem       Date:  1988-08-25       Impact factor: 5.157

5.  Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts.

Authors:  W T Beck; T J Mueller; L R Tanzer
Journal:  Cancer Res       Date:  1979-06       Impact factor: 12.701

6.  HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression.

Authors:  P Martin; T Papayannopoulou
Journal:  Science       Date:  1982-06-11       Impact factor: 47.728

7.  Establishment and characterization of a human histiocytic lymphoma cell line (U-937).

Authors:  C Sundström; K Nilsson
Journal:  Int J Cancer       Date:  1976-05-15       Impact factor: 7.396

8.  Establishment and characterization of a human acute monocytic leukemia cell line (THP-1).

Authors:  S Tsuchiya; M Yamabe; Y Yamaguchi; Y Kobayashi; T Konno; K Tada
Journal:  Int J Cancer       Date:  1980-08       Impact factor: 7.396

9.  MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.

Authors:  M Watanabe; N Komeshima; S Nakajima; T Tsuruo
Journal:  Cancer Res       Date:  1988-12-01       Impact factor: 12.701

10.  Vinblastine photoaffinity labeling of a high molecular weight surface membrane glycoprotein specific for multidrug-resistant cells.

Authors:  A R Safa; C J Glover; M B Meyers; J L Biedler; R L Felsted
Journal:  J Biol Chem       Date:  1986-05-15       Impact factor: 5.157

View more
  1 in total

Review 1.  A comprehensive review of glycosylated bacterial natural products.

Authors:  Sherif I Elshahawi; Khaled A Shaaban; Madan K Kharel; Jon S Thorson
Journal:  Chem Soc Rev       Date:  2015-11-07       Impact factor: 54.564

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.